“Big bull stocks” of the Beijing stock exchange were suddenly bad.
On the evening of January 20, Jinghua Pharmaceutical Group Co.Ltd(002349) holding senxuan pharmaceutical of the Beijing stock exchange disclosed the pre reduction plan of three directors or executives.
Since being given the concept of covid-19 oral medicine by the market, senxuan pharmaceutical’s share price has soared all the way. Disk display, the past 22 trading days, the company’s share price rose 3.4 times, the total market value soared to 13.7 billion yuan.
During the sharp rise, senxuan pharmaceutical issued too many announcements on abnormal fluctuations in stock trading, suggesting risks, saying that there had been no significant changes in the company’s operation and internal and external business environment in the near future.
directors and executives throw out the reduction plan
According to the announcement, Cheng Jian, director of senxuan pharmaceutical, Jiang Chunjuan, director and deputy general manager, as well as CFO and Dong Mi Zhu Shizhang, plan to reduce the shares of the company by centralized bidding from February 18 to August 17.
Senxuan pharmaceutical said that the above-mentioned senior executives are firmly optimistic about the future development of the company, and the reduction plan is required by personal capital needs. The company stressed that the reducing shareholders will decide whether to implement the share reduction plan according to the market conditions, personal capital needs and the company’s share price.
At present, the above three people each hold 100000 shares of senxuan medicine, which were obtained before entering the Beijing stock exchange. According to the latest closing price, the market value of their respective holdings is 3.2 million yuan
source: company announcement
According to the 2020 annual report disclosed by senxuan medicine, Cheng Jian, Jiang Chunjuan and Zhu Shizhang received 684300 yuan, 573200 yuan and 479000 yuan respectively from the company in that year. Among them, Cheng Jian resigned as the general manager of senxuan medicine from February 7, 2021.
The reason why senxuan pharmaceutical’s share reduction plan has attracted much market attention is that the company’s share price has just experienced a sharp rise.
According to chocie data, senxuan pharmaceutical’s share price has stabilized and rebounded since December 21, 2021. As of the closing on January 20, 2022, the company’s share price has increased by 343.83% in these 22 trading days, with a cumulative turnover of RMB 8.492 billion and a cumulative turnover of 523.99%.
The above three market data ranked first in the performance of Beijing stock exchange companies in the same period. In terms of transaction volume, beiteri, the “big brother in market value” of the Beijing stock exchange, was only 3.392 billion yuan in the same period, with a difference of 5.1 billion yuan.
It is worth mentioning that after the share price soared, senxuan medicine’s ranking in the market value ranking of the Beijing stock exchange continued to jump, and now ranks fourth with 13.7 billion yuan.
unexpectedly rose
An investor who has been following the new third board and the Beijing stock exchange for a long time sighed: “senxuan medicine originally had a flat trend in the original selection layer of the new third board. It was the same in the early stage of the opening of the Beijing stock exchange. It didn’t want to be labeled with the” concept “of covid-19 oral medicine” and become a bull stock in seconds. “
Senxuan pharmaceutical was founded in April 2003 and listed on the new third board in August 2014. It entered the selection layer in July 2020 and became one of the first companies of Beijing stock exchange in November 2021. The company’s main business is the R & D, production and sales of APIs, pharmaceutical intermediates and oxygen-containing heterocyclic chemical intermediates.
It is understood that in November 2021, the US Food and Drug Administration (FDA) successively approved the emergency use of two covid-19 oral drugs for the treatment of mild to moderate covid-19 pneumonia. Since then, Chinese manufacturers of APIs and intermediates related to covid-19 oral drugs have become the target of market pursuit.
Dongguan Securities believes that due to the impact of covid-19 pneumonia, the sales and income of dioxane products of senxuan medicine supplied to redcivir API increased.
“The dioxane products produced by the company are mainly used in solvents for pharmaceutical and chemical synthesis. At present, the annual production capacity is 5000 tons. As of the date of disclosure of this announcement, there is no plan to expand the production capacity.” In the announcement disclosed on January 14, senxuan pharmaceutical said that from January 1 to the disclosure date of the announcement, the company did not sign large purchase and sales contracts related to dioxane products, and the sales volume and sales revenue of dioxane products did not change significantly month on month.
Senxuan pharmaceutical stressed that as of January 14, the company had not signed a purchase and sales contract related to dioxane products with Shanghai Junshi Biosciences Co.Ltd(688180) and had not supplied dioxane products to it.
Affected by the sharp rise in raw materials, senxuan pharmaceutical’s profit fell. In the first three quarters of 2021, the company achieved an operating revenue of 398 million yuan, a year-on-year decrease of 2.62%; The net profit attributable to the parent company was 98.3862 million yuan, a year-on-year decrease of 9.75%. Among them, the company’s profit fell by more than 40% in the third quarter of 2021.
